NEW YORK--(BUSINESS WIRE)--The Klein Law Firm announces the commencement of an investigation of Tesaro, Inc. (NASDAQ: TSRO) concerning possible violations of federal securities laws.
On January 12, 2018, Tesaro announced it had updated the U.S. labeling of VARUBI® (rolapitant) injectable emulsion packages after reports that some patients receiving the treatment experienced “Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions.”
If you suffered a loss in Tesaro and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/TSRO-Info-Request-Form-245.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.